Research Presentation Sessions: Interventional Radiology

RPS 2509 - Interventional management of malignant liver lesions

Lectures

1
Introduction by the moderator

Introduction by the moderator

02:00Thomas K. Helmberger, Munich / DE

2
Can microwave ablation of HCC modulate systemic inflammation and immunity? An analysis of factors affecting neutrophil-to-lymphocyte ratio and correlation with local tumour progression

Can microwave ablation of HCC modulate systemic inflammation and immunity? An analysis of factors affecting neutrophil-to-lymphocyte ratio and correlation with local tumour progression

08:00Angelo Della Corte, Milan / IT

3
Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation

08:00Lukas Müller, Mainz / DE

4
Laser-induced thermotherapy (LITT) versus microwave ablation (MWA) in hepatocellular carcinoma (HCC): therapy response and survival rates

Laser-induced thermotherapy (LITT) versus microwave ablation (MWA) in hepatocellular carcinoma (HCC): therapy response and survival rates

08:00Thomas J. Vogl, Frankfurt a. Main / DE

5
Treatment of primary and secondary liver tumours using microwave ablation (MWA): MR elastography as response parameter

Treatment of primary and secondary liver tumours using microwave ablation (MWA): MR elastography as response parameter

08:00Thomas J. Vogl, Frankfurt a. Main / DE

6
Radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC): CT texture analysis of the ablated area to predict local recurrence

Radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC): CT texture analysis of the ablated area to predict local recurrence

08:00Daniele Autelitano, Verona / IT

7
Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: evaluation of the CALLY index

Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: evaluation of the CALLY index

08:00Lukas Müller, Mainz / DE

8
Augmented reality-guided percutaneous thermal ablation of small hepatic tumours: first clinical experience in human patients worldwide

Augmented reality-guided percutaneous thermal ablation of small hepatic tumours: first clinical experience in human patients worldwide

08:00Luigi Solbiati, Rozzano (Milano) / IT

9
Comparison of combined chemoembolisation and microwave ablation with chemoembolisation alone in patients with hepatocellular carcinoma beyond the Milan criteria: a propensity scoring matching study

Comparison of combined chemoembolisation and microwave ablation with chemoembolisation alone in patients with hepatocellular carcinoma beyond the Milan criteria: a propensity scoring matching study

08:00Yu-dong Xiao, Changsha / CN

10
Does lipiodol retention pattern influence the treatment efficacy of computed tomography guided thermal ablation for hepatocellular carcinoma: a propensity scoring matching study

Does lipiodol retention pattern influence the treatment efficacy of computed tomography guided thermal ablation for hepatocellular carcinoma: a propensity scoring matching study

08:00Yu-dong Xiao, Changsha / CN